SLC5A2 and urinary tract infection: While SGLT2 inhibitors are an effective glucose-lowering agent and have substantial benefits in both the treatment of heart failure and chronic kidney disease [10,11,12], a fear of urinary tract infections and the associated impairment of glucose control have somewhat limited their prescription [13].